Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00645086 · ClinicalTrials.gov registry record · Phase 3
Comparative Study of 5 Days of M02-472 Clarithromycin Extended-Release Tablets to 7 Days of Clarithromycin Immediate-Release Tablets for the Treatment of Exacerbation of Chronic Bronchitis
A Phase 3 study, sponsored by Abbott.
- Completed
- Registry status
- Phase 3
- Development phase
- 465
- Enrollment target
NCT00645086 is a Phase 3 study that has completed, run by Abbott. The registered enrollment target is 465 participants.
The verdict
NCT00645086, a Phase 3 study, has completed, sponsored by Abbott.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 465 participants
- Enrollment target
Study Summary
To compare the efficacy of a 5-day course of clarithromycin extended-release tablets (2 x 500 mg QD) with that of a 7-day course of clarithromycin immediate-release tablets (1 x 500 mg BID) in the treatment of acute bacterial exacerbation of chronic bronchitis.
Interventions
- DRUG clarithromycin extended-release tablets
- DRUG clarithromycin immediate-release tablets
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 465 participants |
| Start Date | 2002-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00645086
The ClinicalTrials.gov registry entry for NCT00645086 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 465 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abbott, which has 181 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which clarithromycin extended-release tablets is the first listed.
NCT00645086 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00645086 about?
NCT00645086 is a clinical study titled "Comparative Study of 5 Days of M02-472 Clarithromycin Extended-Release Tablets to 7 Days of Clarithromycin Immediate-Release Tablets for the Treatment of Exacerbation of Chronic Bronchitis". To compare the efficacy of a 5-day course of clarithromycin extended-release tablets (2 x 500 mg QD) with that of a 7-day course of clarithromycin immediate-release tablets (1 x 500 mg BID) in the treatment of acute bacterial exacerbation of chronic bronchitis.
What is the current status of trial NCT00645086?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 465 participants. The study started on 2002-12.
What interventions are being tested in trial NCT00645086?
The interventions under investigation include: clarithromycin extended-release tablets (DRUG), clarithromycin immediate-release tablets (DRUG).
Who is sponsoring clinical trial NCT00645086?
This trial is sponsored by Abbott, which has 181 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.